Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trialChristopher Koh, Theo Heller, David E. Kleiner et al.|The Lancet Infectious Diseases|2015Cited by 262
Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug usersMarian Major, Harel Dahari, Behzad Hajarizadeh et al.|Science Translational Medicine|2018Cited by 46